Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
Carlo MessinaMartina CatalanoGiandomenico RovielloAnnalice GandiniMarco MaruzzoUgo De GiorgiPaolo PedrazzoliAndrea SbranaPaolo Andrea ZucalCristina MasiniEmanuele NaglieriGiuseppe ProcopioMichele MilellaFabio CatalanoLucia FratinoStefania PipitoneRiccardo RicottaStefano PanniVeronica MollicaMariella SoraruVeronica PratiFrancesco AtzoriMarilena Di NapoliMarco MessinaFranco MorelliGiuseppe PratiFranco NoleAndrea MalgeriMarianna TudiniFrancesca VignaniAlessia CavoAlessio SignoriGiuseppe Luigi BannaPasquale RescignoSebastiano ButiSara Elena RebuzziGiuseppe FornariniPublished in: Cancer immunology, immunotherapy : CII (2024)
This retrospective analysis sheds light on factors associated with long-term response to nivolumab in mRCC. Understanding these clinical features will be essential for selecting patients who may mostly benefit from immunotherapy.
Keyphrases